Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

NCT Number	NCT07132801
Lead Sponsor	Qualia Life Sciences
Conditions	NAD, NAD+ Levels in the Blood
Enrollment	180 participants
Start Date	2025-10-13
Primary Completion	2025-11-30 (estimated)
Study Completion	2025-12-15 (estimated)
Updated on ClinicalTrials.gov	2025-08-20